DexCom (NASDAQ:DXCM) Given New $100.00 Price Target at JPMorgan Chase & Co.

DexCom (NASDAQ:DXCM – Free Report) had its price objective decreased by JPMorgan Chase & Co. from $160.00 to $100.00 in a report issued on Tuesday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the medical device company’s stock. Several other equities research analysts have also issued reports on the company. […]

Related Keywords

United States , ,Canaccord Genuity Group ,Rock Asset Management ,Dexcom Inc ,Jpmorgan Chase Co ,Resources Investment Advisors ,Dexcom Company Profile ,Securities Exchange Commission ,Vontobel Holding Ltd ,Barclays ,Financial Counselors Inc ,Citigroup ,Free Report ,Genuity Group ,Moderate Buy ,Com Stock Down ,Get Free Report ,Director Bridgette ,Exchange Commission ,Investment Advisors ,Trail Advisors ,Spouting Rock Asset Management ,Dexcom Share ,Dexcom Real Time ,Dexcom Daily ,Dexcom ,Nasdaq Dxcm ,Dxcm ,Medical ,25213110 ,Lower Price Target ,